Literature DB >> 23076797

Long-term results and prognostic factors in resected pancreatic body and tail adenocarcinomas.

Vinayak S Rohan1, Jun-Te Hsu, Keng-Hao Liu, Chun-Nan Yeh, Ta-Sen Yeh, Yi-Yin Jan, Tsann-Long Hwang.   

Abstract

BACKGROUND: Adenocarcinoma of the body and tail of the pancreas are more often than not inoperable to begin with. Factors predicting the prognosis in the resected tumors of pancreatic body and tail were analyzed.
METHODS: Between 1989 and 2006, 43 patients with adenocarcinoma of the body and tail of the pancreas underwent resection at Chang Gung Memorial Hospital, Taoyuan, Taiwan. Univariate and multivariate analysis of clinicopathological factors affecting the prognosis were analyzed.
RESULTS: Totally, 32 patients were available for the analysis. The median follow-up was 13.6 months (1.5-87.5 months). The median survival time was 14.2 months and the 1-, 3-, and 5-year survival rates were 58.1, 25.8, and 6.5 %, respectively. On univariate analysis, the factors which influenced the survival were tumor size >4 cm (p=0.004), lymphatic invasion (p=0.001), and positive resection margin (p=0.030). On multivariate analysis, only the tumor size and the lymphatic invasion were independent prognostic factors.
CONCLUSION: Even after macroscopic curative resection, the prognosis remains poor for pancreatic body and tail adenocarcinoma. Early diagnosis is the key to achieving long-term survival. Newer effective adjuvant treatment after curative resection is needed to improve the survival.

Entities:  

Mesh:

Year:  2013        PMID: 23076797     DOI: 10.1007/s12029-012-9448-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  19 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Lymph node metastasis in carcinoma of the body and tail of the pancreas.

Authors:  A Nakao; A Harada; T Nonami; T Kaneko; S Nomoto; H Koyama; N Kanazumi; N Nakashima; H Takagi
Journal:  Br J Surg       Date:  1997-08       Impact factor: 6.939

3.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

4.  Ductal adenocarcinoma of the body and tail of the pancreas.

Authors:  C Sperti; C Pasquali; S Pedrazzoli
Journal:  J Am Coll Surg       Date:  1997-09       Impact factor: 6.113

5.  Survival for 25 years following partial pancreatectomy for carcinoma of the body of the pancreas.

Authors:  A Saltzman; A Horvitz; J Dyckman
Journal:  Mt Sinai J Med       Date:  1987-06

6.  Carcinoma of the body and tail of the pancreas.

Authors:  I H Nordback; R H Hruban; J K Boitnott; H A Pitt; J L Cameron
Journal:  Am J Surg       Date:  1992-07       Impact factor: 2.565

7.  Onset symptoms and tumor locations as prognostic factors of pancreatic cancer.

Authors:  Ichiro Watanabe; Satoshi Sasaki; Masaru Konishi; Toshio Nakagohri; Kazuto Inoue; Tatsuya Oda; Taira Kinoshita
Journal:  Pancreas       Date:  2004-03       Impact factor: 3.327

8.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas.

Authors:  H Ozaki; T Kinoshita; T Kosuge; J Yamamoto; K Shimada; K Inoue; Y Koyama; K Mukai
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

10.  Results of extensive surgery for pancreatic carcinoma.

Authors:  T Nagakawa; M Nagamori; F Futakami; Y Tsukioka; M Kayahara; T Ohta; K Ueno; I Miyazaki
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860

View more
  4 in total

1.  Impact of celiac neurolysis on survival in patients with pancreatic cancer.

Authors:  Larissa L Fujii-Lau; William R Bamlet; Jason S Eldrige; Suresh T Chari; Ferga C Gleeson; Barham K Abu Dayyeh; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Elizabeth Rajan; Mark D Topazian; Santhi S Vege; Kenneth K Wang; Maurits J Wiersema; Michael J Levy
Journal:  Gastrointest Endosc       Date:  2015-03-20       Impact factor: 9.427

2.  Rare long-term survivors of pancreatic adenocarcinoma without curative resection.

Authors:  Stephen Y Oh; Alicia Edwards; Margaret T Mandelson; Bruce Lin; Russell Dorer; W Scott Helton; Richard A Kozarek; Vincent J Picozzi
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

3.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.

Authors:  Burcu Saka; Serdar Balci; Olca Basturk; Pelin Bagci; Lauren M Postlewait; Shishir Maithel; Jessica Knight; Bassel El-Rayes; David Kooby; Juan Sarmiento; Takashi Muraki; Irma Oliva; Sudeshna Bandyopadhyay; Gizem Akkas; Michael Goodman; Michelle D Reid; Alyssa Krasinskas; Rhonda Everett; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2016-01-29       Impact factor: 5.344

4.  Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria.

Authors:  Yang Li; Chuan-Gang Tang; Yu Zhao; Wu-You Cao; Guo-Feng Qu
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.